Corcept Therapeutics (CORT) EBT (2010 - 2026)

Corcept Therapeutics has disclosed EBT across 17 years of filings, most recently posting -$44.7 million for Q1 2026.

• EBT for Q1 2026 came in at -$44.7 million, down 564.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (down 91.09% YoY), and the FY2025 annual result was $66.5 million, down 58.84% from the prior year.
• EBT came in at -$44.7 million for Q1 2026 at Corcept Therapeutics, down from $9.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $52.9 million in Q3 2024 to a low of -$44.7 million in Q1 2026.
• The 5-year median for EBT is $32.0 million (2024), against an average of $24.9 million.
• Across the five-year window, EBT jumped 89.83% in 2024 and sank 564.91% in 2026, its largest moves.
• Corcept Therapeutics' EBT stood at $24.3 million in 2022, then soared by 51.63% to $36.8 million in 2023, then declined by 13.17% to $32.0 million in 2024, then tumbled by 68.99% to $9.9 million in 2025, then plunged by 551.21% to -$44.7 million in 2026.
• The last three EBT figures came in at -$44.7 million (Q1 2026), $9.9 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.